type 1 diabetes
Endocrinology · 2006–2025
8decisions
4medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| insulin degludec Treatment of type 1 diabetes mellitus in patients aged 1 year or older requiring basal insulin therapy. | Jul 2025 | Recommended with restriction | input received DANII Foundation · Diabetes Alliance · Australian Diabetes Society |
| insulin aspart Treatment of diabetes mellitus. Truvelog is a biosimilar to the reference brand NovoRapid, indicated for use under the same circumstances as existing NovoRapid… | Nov 2021 | Recommended | none received |
| insulin glargine Treatment of type 1 and type 2 diabetes mellitus. A biosimilar brand of insulin glargine for patients requiring basal insulin therapy. | Jul 2018 | Recommended | none received |
| insulin glargine Once daily subcutaneous administration in the treatment of type 1 diabetes mellitus in adults and children and type 2 diabetes mellitus in adults who require… | Mar 2015 | Recommended | no section in document |
| insulin detemir Treatment of Type 1 or Type 2 diabetes patients requiring intensive insulin therapy with 3 or more injections of insulin per day, and Type 1 patients with a… | Mar 2006 | Recommended with restriction | no section in document |
| insulin glargine For the treatment of Type 1 diabetes; For the treatment of Type 2 diabetes when used in combination with three or more prandial doses of insulin per day; For… | Mar 2006 | Recommended | no section in document |
| insulin detemir Treatment of Type 1 diabetes requiring intensive insulin therapy with basal-bolus insulin regimen. | Mar 2006 | Recommended with restriction | no section in document |
| insulin glargine Once daily subcutaneous administration in the treatment of Type 1 diabetes mellitus in adults and children and Type 2 diabetes mellitus in adults who require… | Mar 2006 | Recommended | no section in document |
Who spoke
DANII Foundation · Diabetes Alliance · Australian Diabetes Society
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.